diallyl phosphite | 23679-20-1

• 分子结构分类: 有机化合物 - 有机氧化合物 - 有机含氧阴离子化合物
• 英文名称: diallyl phosphite
• 英文别名: Bis(prop-2-enyl) hydrogen phosphite
• CAS: 23679-20-1
• 化学式: C₆H₁₁O₃P
• 分子量: 162.125
• InChiKey: OXLDKMFHLBAHLV-UHFFFAOYSA-N

物化性质

• 沸点：
  97.5-98.5 °C(Press: 8 Torr)
• 密度：
  1.0800

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  10
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  38.7
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2920909090

反应信息

• 作为反应物：
  描述：

  diallyl phosphite 在 烯丙醇 作用下， 生成 [9-(2-hydroxy-ethyl)-2,9a-dimethyl-5,9,9a,10-tetrahydro-pyrimido[4,5-d]thiazolo[3,4-a]pyrimidin-7-yl]-phosphonic acid diallyl ester
  参考文献：
  名称：

  Takamizawa,A. et al., Chemical and pharmaceutical bulletin, 1968, vol. 16, # 9, p. 1764 - 1772

  摘要：

  DOI：
• 作为产物：
  描述：

  烯丙醇 在 三乙胺 、 三氯化磷 作用下， 以 四氢呋喃 为溶剂， 反应 1.0h， 生成 diallyl phosphite
  参考文献：
  名称：

  [EN] PHOSPHOLIPID ETHER CONJUGATES AS CANCER-TARGETING DRUG VEHICLES
  [FR] CONJUGUÉS D'ÉTHER PHOSPHOLIPIDIQUE UTILISÉS EN TANT QUE VÉHICULES DE MÉDICAMENTS CIBLANT LE CANCER

  摘要：

  本文披露了能够针对广泛范围的肿瘤细胞的治疗化合物。本公开还涉及包含这些治疗化合物的组合物、制造这些治疗化合物的方法，以及包括给予这些治疗化合物的方法治疗癌症。

  公开号：

  WO2021050917A1

文献信息

• NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME
  申请人：Ryono Denis E.

  公开号：US20080009465A1

  公开（公告）日：2008-01-10

  Compounds are provided which are phosphonate and phosphinate activators and thus are useful in treating diabetes and related diseases and have the structure wherein is a heteroaryl ring; R 4 is —(CH 2 ) n -Z-(CH 2 ) m —PO(OR 7 )(OR 8 ), —(CH 2 ) n Z-(CH 2 ) m —PO(OR 7 )R g , —(CH 2 ) n -Z-(CH 2 ) m —OPO(OR 7 )R g , —(CH 2 ) n Z—(CH 2 ) m —OPO(R 9 )(R 10 ), or —(CH 2 ) n Z—(CH 2 ) m —PO(R 9 )(R 10 ); R 5 and R 6 are independently selected from H, alkyl and halogen; Y is R 7 (CH 2 ) s or is absent; and X, n, Z, m, R 4 , R 5 , R 6 , R 7 , and s are as defined herein; or a pharmaceutically acceptable salt thereof. A method for treating diabetes and related diseases employing the above compounds is also provided.

  提供了磷酸酯和磷酸酯激活剂，因此在治疗糖尿病和相关疾病方面非常有用，并具有以下结构： 其中 是杂环芳基环； R 4 为—(CH 2 ) n -Z-(CH 2 ) m —PO(OR 7 )(OR 8 )、—(CH 2 ) n Z-(CH 2 ) m —PO(OR 7 )R g 、—(CH 2 ) n -Z-(CH 2 ) m —OPO(OR 7 )R g 、—(CH 2 ) n Z—(CH 2 ) m —OPO(R 9 )(R 10) 或—(CH 2 ) n Z—(CH 2 ) m —PO(R 9 )(R 10) ； R 5 和R 6 分别选择自H、烷基和卤素； Y为R 7 (CH 2 ) s 或不存在；以及 X、n、Z、m、R 4 、R 5 、R 6 、R 7 和s如本文所定义；或其药用盐。 还提供了一种利用上述化合物治疗糖尿病和相关疾病的方法。
• Novel Thiazole Inhibitors of Fructose 1,6-Bishosphatase
  申请人：Dang Qun

  公开号：US20070225259A1

  公开（公告）日：2007-09-27

  Compounds of Formula I, their prodrugs and salts, their preparation and their uses are described.

  公式I的化合物，它们的前药和盐，它们的制备以及它们的用途被描述了。
• EPOTHILONE DERIVATIVES, METHOD FOR PRODUCING SAME AND THEIR PHARMACEUTICAL USE
  申请人：——

  公开号：US20030144523A1

  公开（公告）日：2003-07-31

  This invention relates to the new epothilone derivatives of general formula I, 1 in which substituents Y, Z R 2a , R 2b , R 3 , R 4a , R 4b , D—E, R 5 , R 6 , R 7 , R 8 and X have the meanings that are indicated in more detail in the description. The new compounds interact with tubulin by stabilizing microtubuli that are formed. They are able to influence the cell-splitting in a phase-specific manner and are suitable for treating malignant tumors, for example, ovarian, stomach, colon, adeno-, breast, lung, head and neck carcinomas, malignant melanomas, acute lymphocytic and myelocytic leukemia. In addition, they are suitable for anti-angiogenesis therapy as well as for treatment of chronic inflammatory diseases (psoriasis, arthritis). To avoid uncontrolled proliferation of cells and for better compatibility of medical implants, they can be applied or introduced into polymer materials. The compounds according to the invention can be used alone or to achieve additive or synergistic actions in combination with other principles and classes of substances that can be used in tumor therapy.

  本发明涉及具有通式I的新埃波替隆衍生物，其中取代基Y、Z、R2a、R2b、R3、R4a、R4b、D—E、R5、R6、R7、R8和X的含义在描述中更详细地指出。这些新化合物通过与微管蛋白的相互作用来稳定形成的微管。它们能够以阶段特异性的方式影响细胞分裂，并适用于治疗恶性肿瘤，例如卵巢、胃、结肠、腺体、乳腺、肺、头颈癌、恶性黑色素瘤、急性淋巴细胞和骨髓细胞白血病。此外，它们还适用于抗血管生成治疗以及治疗慢性炎性疾病（银屑病、关节炎）。为了避免细胞的不受控制的增殖以及提高医疗植入物的相容性，它们可以应用于或引入到聚合物材料中。根据发明的化合物可以单独使用，也可以与其他可用于肿瘤治疗的原理和物质类别结合使用，以实现相加或协同作用。
• [EN] NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME<br/>[FR] NOUVEAUX ACTIVATEURS DE LA GLUCOKINASE ET MÉTHODES D'UTILISATION DESDITS ACTIVATEURS
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2011130459A1

  公开（公告）日：2011-10-20

  Compounds are provided which are activators of the enzyme glucokinase and thus are useful in treating diabetes and related diseases, which compounds have the structure wherein R1, R2, R3, R4, R5, R6, Y and X are as defined herein or a pharmaceutically acceptable salt thereof. A method for treating diabetes and related disease employing the above compounds is also provided.

  提供了一些化合物，这些化合物是葡萄糖激酶的激活剂，因此在治疗糖尿病和相关疾病方面很有用，这些化合物的结构式中，R1、R2、R3、R4、R5、R6、Y和X如本文所述，或其药用可接受盐。还提供了一种使用上述化合物治疗糖尿病和相关疾病的方法。
• [EN] BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS<br/>[FR] PYRAZOLES BICYCLIQUES EN TANT QU'INHIBITEURS DE PROTÉINES KINASES
  申请人：NERVIANO MEDICAL SCIENCES SRL

  公开号：WO2010070060A1

  公开（公告）日：2010-06-24

  3,4-diaryl-bicyclicpyrazole derivatives of formula (I) as defined in the specification, and pharmaceutically acceptable salts thereof, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful, in therapy, in the treatment of diseases associated with a disregulated protein kinase activity, like cancer.

  公开了规范中定义的式(I)的3,4-二芳基-双环吡唑衍生物及其药学上可接受的盐，其制备方法和包含它们的药物组合物；发明的化合物可能在治疗中对治疗与蛋白激酶活性失调相关的疾病，如癌症，具有用处。